抗炎治疗用于动脉粥样硬化性卒中预防
该综述指出动脉粥样硬化性缺血性卒中是复发风险最高的卒中亚型,炎症在其发病机制中起作用,大型心血管结局试验显示抗炎治疗可降低残余血管风险,低剂量秋水仙碱已获批用于动脉粥样硬化患者的心血管风险降低。但首个秋水仙碱卒中试验结果中性或矛盾,综述汇总了临床前、遗传和流行病学证据及已完成和正在进行的卒中特异性试验,提出需精准医学靶向已有动脉粥样硬化和血管炎症的患者。
要点
- 动脉粥样硬化性卒中复发风险最高,当前二级预防未充分解决残余风险。
- 低剂量秋水仙碱已获批用于动脉粥样硬化患者心血管风险降低,但卒中试验结果不一。
- 需精准医学识别已有动脉粥样硬化和血管炎症的卒中患者以指导抗炎治疗。
核心结论
- 抗炎治疗在动脉粥样硬化性卒中预防中转化困难,首个秋水仙碱试验结果中性或矛盾,需精准医学靶向特定患者。
研究设计与样本
- 综述类研究,检索并汇总临床前、遗传和流行病学文献、心血管结局试验及已完成和正在进行的卒中特异性试验。
主要发现
- 动脉粥样硬化性缺血性卒中在卒中亚型中复发风险最高。
- 近期大型心血管结局试验显示抗炎治疗可降低冠心病患者残余血管风险。
- 低剂量秋水仙碱已获批用于动脉粥样硬化患者心血管风险降低。
- 首个秋水仙碱卒中试验显示中性或矛盾结果。
临床怎么用
- 在卒中二级预防中,需考虑动脉粥样硬化性卒中的炎症机制及精准医学策略,识别已有动脉粥样硬化和血管炎症的患者。
局限性
- 缺血性卒中的病因异质性可能掩盖抗炎治疗效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ischemic stroke caused by atherosclerosis is associated with the highest risk of recurrence among stroke etiologies, highlighting a residual risk that current secondary prevention strategies fail to address. Multiple lines of research implicate inflammation in the pathogenesis of atherosclerosis, including recent large cardiovascular outcome trials demonstrating that anti-inflammatory therapies can lower residual vascular risk in patients with coronary artery disease. Notably, low-dose colchicine, a long-used anti-inflammatory drug, has received approval for cardiovascular risk reduction in patients with atherosclerosis. However, translation of anti-inflammatory treatments to patients with ischemic stroke has been challenging, with the first colchicine trials showing neutral or conflicting results. In this study, we review the preclinical, genetic, and epidemiologic literature linking inflammation to atherosclerotic stroke; examine key findings of cardiovascular outcome trials for stroke prevention; and summarize completed and ongoing stroke-specific trials. We discuss the etiologic heterogeneity of ischemic stroke that may obscure anti-inflammatory treatment effects, highlighting the need for precision medicine approaches targeting patients with established atherosclerosis and vascular inflammation. Finally, we provide an overview of the emerging anti-inflammatory therapeutics that are under development for atheroprotection and outline a translational roadmap to accelerate clinical impact in stroke prevention.
引用
- Georgakis MK, Melton P, Živković L, et al. Anti-Inflammatory Therapies for Atherosclerotic Stroke Prevention. Neurology. 2025. PMID: 41043091. doi:10.1212/WNL.0000000000214214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。